Can yearly MRIs catch second cancers in retinoblastoma survivors?
NCT ID NCT03026998
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether yearly MRI scans can find new head and neck or brain cancers early in people who had hereditary retinoblastoma and were treated with radiation. Researchers will follow 88 participants for 10 years to see if early detection leads to better surgery outcomes. The goal is to improve survival and preserve vision.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that regular MRI screening helps catch new cancers early, leading to better treatment and survival for people with hereditary retinoblastoma.
- What could go wrong
- This is an observational study, not a treatment trial. It may not prove that screening improves outcomes, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
88 people
The number who actually took part.
- Started
-
Mar 2017
- Expected to finish
-
Mar 2034
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
7 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Personal history of hereditary retinoblastoma (i.e., familial history of retinoblastoma, or bilateral retinoblastoma, or unilateral multifocal retinoblastoma, or identified germline RB1 mutation or 13q deletion) * External beam radiation therapy (EBRT) used for retinoblastoma treatment * Age at inclusion greater or equal to 7 years old. * Time period between the end of EBRT and inclusion date of 5 years or more * Written informed consent signed by patient (or legal representative) Exclusion Criteria: * Personal history of non-familial unilateral unifocal retinoblastoma without RB1 germline mutation. * Personal history of second primary neoplasm occurring within radiation fields * Contraindication for MRI (pacemaker, intraocular metallic foreign body, defibrillators or other implanted electronic devices, intracranial ferro-magnetic clips) or associated conditions preventing from MR examination (intraocular prostheses and implants are not a contraindication for MRI; orthodontic metallic devices are not a contraindication but might decrease the image quality and should be removed, if possible) * Patients unable to comply with follow-up study requirements, for any geographical, social or psychological reason
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hereditary retinoblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Curie
Paris, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.